SMC
ALXN

S. Muoio & Co’s Alexion Pharmaceuticals ALXN Stock Holding History

S. Muoio & Co’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-24,000
Closed -$4.41M – 122
2021
Q2 		$4.41M Hold
24,000
– – 3.74% 3
2021
Q1 		$3.67M Buy
24,000
+4,000
+20% +$619K 3.93% 2
2020
Q4 		$3.13M Buy
+20,000
New +$2.57M 3.39% 5

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

S. Muoio & Co's ALXN Position: Q3 2021 in Review

S. Muoio & Co sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 24,000 shares — an estimated $4.41M sold.

S. Muoio & Co first reported a position in ALXN in Q4 2020 and held it in 3 quarters. The position peaked at $4.41M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • S. Muoio & Co reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • S. Muoio & Co sold 24,000 Alexion Pharmaceuticals shares in Q3 2021, an estimated $4.41M.
  • S. Muoio & Co first reported a position in Alexion Pharmaceuticals in Q4 2020 and held it in 3 quarters.
  • S. Muoio & Co's Alexion Pharmaceuticals position peaked at $4.41M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on S. Muoio & Co's 13F filing for Q3 2021, filed 15 Nov 2021.